Passive hyperimmune antibody therapy in the treatment of anthrax
OwnerJoshua Levyinventor
Life of this patent
Estimating the term…
Abstract
A method of treatment of severe anthrax infection particularly inhalation pneumonia or gastrointestinal anthrax antigen by the passive transfer to infected patients of plasma or plasma fractionated derivatives, such as gammaglobulins or antibodies, monclonal or polyclonal, with high titer neutralizing antibodies against Bacillus anthracis or its toxins. The plasma or fractionated plasma derivatives are derived from previously vaccinated individuals with anthrax vaccine, or any antigen or toxin antigen of Bacillus anthracis, including protective antigen (PA), lethal factor (LF) and/or oedema factor (OF).
Claims14
A method of treatment for patients severely infected with anthrax using passive hyperimmune antibody therapy, comprising:
- deriving a supply of plasma from previously vaccinated individuals;
- processing the plasma derived therefrom to provide a preparation of gammaglobulins having a high titer of neutralizing antibodies to anthrax, the processed plasma being sterilized and free of any impurities;
- and
- administering the processed plasma to the infected patient.
Dependencies are inferred from the claim text.